Biomarker for Farber Disease (BioFarber)

Splenomegaly

PREDIGA 2: Spanish Acronym of “Educational and Diagnostic Project for Gaucher and ASMD” Incentive Spirometry and Upper Abdominal Laparoscopic Surgery An Observational Study in Patients With Unexplained Splenomegaly Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Biomarker for Farber Disease (BioFarber) Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Biomarker for Sly Disease (MPS VII) (BioSly) CINC424A2X01B Rollover Protocol Biomarker for Gaucher Disease: BioGaucher (BioGaucher) The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department Spleen Size in Peripheral Blood Stem Cell Donors Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination Estimation of Spleen by Residents With VScan Ultrasound Estimation of Spleen Size